Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A systematic review

Virology Journal

Volumn 8, Issue , 2011, Pages

  Zhao, Shu Shan ^a,b   Tang, Lan Hua ^a,b   Dai, Xia Hong ^a   Wang, Wei ^c   Zhou, Rong Rong ^a   Chen, Li Zhang ^c   Fan, Xue Gong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; COCHRANE LIBRARY; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG POTENCY; EMBASE; FATIGUE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDLINE; META ANALYSIS; NAUSEA; NONHUMAN; REVIEW; RHINOPHARYNGITIS; SEROCONVERSION; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS B VIRUS;

ADENINE; ANTIVIRAL AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 79952324747     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-111     Document Type: Review

References (25)

1. Hepatitis B today. M Safioleas NJ Lygidakis C Manti, Hepatogastroenterology 2007 54 545 548 17523319 (Pubitemid 46724727)
2. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. GA Poland RM Jacobson, N Engl J Med 2004 351 2832 2838 10.1056/NEJMcp041507 15625334 (Pubitemid 40051907)
3. Telbivudine in the treatment of chronic hepatitis B. K Nash, Adv Ther 2009 26 155 169 10.1007/s12325-009-0004-y 19225726
4. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto P Marcellin SG Lim Z Goodman MS Wulfsohn,, et al. N Engl J Med 2003 348 800 807 10.1056/NEJMoa021812 12606734 (Pubitemid 36245756)
5. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. P Marcellin TT Chang SG Lim MJ Tong W Sievert ML Shiffman L Jeffers Z Goodman MS Wulfsohn S Xiong,, et al. N Engl J Med 2003 348 808 816 10.1056/NEJMoa020681 12606735 (Pubitemid 36245757)
6. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. EQ Chen LC Wang J Lei L Xu H Tang, Virol J 2009 6 163 10.1186/1743-422X-6-163 19818142
7. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. L Jiang LN Yan, World J Gastroenterol 2010 16 2468 2475 10.3748/wjg.v16.i20.2468 20503446
8. Personal view: the management of chronic hepatitis B infection. M Sherman, Aliment Pharmacol Ther 2006 23 857 869 10.1111/j.1365-2036.2006.02840.x 16573788
9. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. WEt Delaney, J Antimicrob Chemother 2007 59 827 832 10.1093/jac/dkl551 17332007
10. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. RT Schooley P Ruane RA Myers G Beall H Lampiris D Berger SS Chen MD Miller E Isaacson AK Cheng, AIDS 2002 16 1257 1263 10.1097/00002030-200206140-00008 12045491 (Pubitemid 34666660)
11. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. O Lada Y Benhamou A Cahour C Katlama T Poynard V Thibault, Antivir Ther 2004 9 353 363 15259898 (Pubitemid 38878751)
12. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. Y Benhamou R Tubiana V Thibault, New England Journal of Medicine 2003 348 177 178 10.1056/NEJM200301093480218 12519935 (Pubitemid 36056731)
13. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. K Lacombe J Gozlan PY Boelle L Serfaty F Zoulim AJ Valleron PM Girard, AIDS 2005 19 907 915 10.1097/01.aids.0000171404.07995.5c 15905671 (Pubitemid 40834933)
14. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. P Marcellin EJ Heathcote M Buti E Gane RA de Man Z Krastev G Germanidis SS Lee R Flisiak K Kaita,, et al. N Engl J Med 2008 359 2442 2455 10.1056/NEJMoa0802878 19052126
15. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. F van Bommel RA de Man H Wedemeyer K Deterding J Petersen P Buggisch A Erhardt D Huppe K Stein J Trojan,, et al. Hepatology 2010 51 73 80 19998272
16. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. K Lacombe J Gozlan A Boyd PY Boelle P Bonnard JM Molina P Miailhes C Lascoux-Combe L Serfaty F Zoulim PM Girard, Antivir Ther 2008 13 705 713 18771054
17. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). HW Hann HB Chae SR Dunn, Hepatol Int 2008 2 244 249 10.1007/s12072-008-9045-6 19669311 (Pubitemid 351650155)
18. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. MG Peters J Andersen P Lynch T Liu B Alston-Smith CL Brosgart JM Jacobson VA Johnson RB Poflard JF Rooney,, et al. Hepatology 2006 44 1110 1116 10.1002/hep.21388 17058225 (Pubitemid 44748362)
19. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. F van Bommel T Wunsche S Mauss P Reinke A Bergk D Schurmann B Wiedenmann T Berg, Hepatology 2004 40 1421 1425 10.1002/hep.20464 15565615 (Pubitemid 39657017)
20. Assessing the quality of reports of randomized clinical trials: is blinding necessary? AR Jadad RA Moore D Carroll C Jenkinson DJ Reynolds DJ Gavaghan HJ McQuay, Control Clin Trials 1996 17 1 12 10.1016/0197-2456(95)00134- 4 8721797 (Pubitemid 26120810)
21. Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review. S Zhao L Tang X Fan L Chen R Zhou X Dai, Virol J 2010 7 211 10.1186/1743-422X-7-211 20815890
22. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. YF Yang W Zhao YD Zhong YJ Yang L Shen N Zhang P Huang, Antiviral Res 2008 77 136 141 10.1016/j.antiviral.2007.10.014 18078676
23. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. AY Hui HL Chan AY Cheung G Cooksley JJ Sung, Aliment Pharmacol Ther 2005 22 519 528 10.1111/j.1365-2036.2005.02616.x 16167968 (Pubitemid 41360798)
24. Systematic reviews in health care: Assessing the quality of controlled clinical trials. P Juni DG Altman M Egger, BMJ 2001 323 42 46 10.1136/bmj.323.7303.42 11440947 (Pubitemid 32682008)
25. Publication bias in meta-analysis: its causes and consequences. A Thornton P Lee, J Clin Epidemiol 2000 53 207 216 10.1016/S0895-4356(99)00161-4 10729693 (Pubitemid 30151226)